Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Country | United States |
Founded | 2009 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 19 |
CEO | Yuval Cohen |
Contact Details
Address: 500 River Ridge Drive Norwood, Massachusetts 02062 United States | |
Phone | 617 963 0100 |
Website | corbuspharma.com |
Stock Details
Ticker Symbol | CRBP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001595097 |
CUSIP Number | 21833P103 |
ISIN Number | US21833P3010 |
Employer ID | 46-4348039 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Yuval Cohen Ph.D. | Chief Executive Officer and Director |
Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
Lindsey Smith | Head of Corporate Communications and Patient Advocacy |
Christina Bertsch | Vice President of Human Resources |
Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 4, 2024 | 8-K | Current Report |
Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Sep 4, 2024 | 144 | Filing |
Sep 3, 2024 | 8-K | Current Report |
Aug 20, 2024 | 8-K | Current Report |
Aug 6, 2024 | 8-K | Current Report |
Aug 6, 2024 | 10-Q | Quarterly Report |